These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. [Osteoporosis in patients under treatment for cancer and the possibilities for prevention and treatment]. Eekhoff EM; Pinedo HM; Lips P Ned Tijdschr Geneeskd; 2007 Jun; 151(25):1388-93. PubMed ID: 17668601 [TBL] [Abstract][Full Text] [Related]
23. Glucocorticoid-induced osteoporosis: a review on pathophysiology and treatment options. De Nijs RN Minerva Med; 2008 Feb; 99(1):23-43. PubMed ID: 18299694 [TBL] [Abstract][Full Text] [Related]
24. Who will benefit from antiresorptive treatment (bisphosphonates)? Papapoulos SE Best Pract Res Clin Rheumatol; 2005 Dec; 19(6):965-73. PubMed ID: 16301190 [TBL] [Abstract][Full Text] [Related]
27. Bisphosphonates effective in preventing bone complications associated with androgen deprivation therapy. J Support Oncol; 2006 Feb; 4(2):99-100. PubMed ID: 16499137 [No Abstract] [Full Text] [Related]
28. Secondary prevention of osteoporosis: Calcium, Vitamin D and bisphosphonate prescribing following distal radial fracture. Talbot JC; Elener C; Praveen P; Shaw DL Injury; 2007 Nov; 38(11):1236-40. PubMed ID: 17572417 [TBL] [Abstract][Full Text] [Related]
29. Bone mineral density changes on androgen deprivation therapy for prostate cancer and response to antiresorptive therapy. Yaturu S; DjeDjos S; Alferos G; Deprisco C Prostate Cancer Prostatic Dis; 2006; 9(1):35-8. PubMed ID: 16276350 [TBL] [Abstract][Full Text] [Related]
30. Alfacalcidol versus plain vitamin D in inflammation induced bone loss. Scharla SH; Schacht E; Lempert UG J Rheumatol Suppl; 2005 Sep; 76():26-32. PubMed ID: 16142848 [TBL] [Abstract][Full Text] [Related]
31. [Bisphosphonate therapy for osteoporosis and bone strength]. Kishimoto H Clin Calcium; 2006 Sep; 16(9):1513-19. PubMed ID: 16951477 [TBL] [Abstract][Full Text] [Related]
32. High prevalence of early-onset osteopenia/osteoporosis after allogeneic stem cell transplantation and improvement after bisphosphonate therapy. Yao S; McCarthy PL; Dunford LM; Roy DM; Brown K; Paplham P; Syta M; Lamonica D; Smiley S; Battiwalla M; Padmanabhan S; Hahn T Bone Marrow Transplant; 2008 Feb; 41(4):393-8. PubMed ID: 17994116 [TBL] [Abstract][Full Text] [Related]
33. Evaluation and management of bone disease and fractures post transplant. Bia M Transplant Rev (Orlando); 2008 Jan; 22(1):52-61. PubMed ID: 18631858 [TBL] [Abstract][Full Text] [Related]
34. Comparative study of the protective effect of different intravenous bisphosphonates on the decrease in bone mineral density in patients submitted to radical prostatectomy undergoing androgen deprivation therapy. A prospective open-label controlled study. Rodrigues P; Hering FO; Bruna P; Meller A; Afonso Y Int J Urol; 2007 Apr; 14(4):317-20. PubMed ID: 17470161 [TBL] [Abstract][Full Text] [Related]
35. Vitamin D receptor genotypes and response to zoledronic acid therapy in thalassemia-induced osteoporosis. Otrock ZK; Mahfouz RA; Charafeddine KM; Rayes RF; Zahed LF; Taher AT Ann Hematol; 2008 Nov; 87(11):947-8. PubMed ID: 18443790 [No Abstract] [Full Text] [Related]